Form 4: Tenaya Therapeutics Director Receives Stock Option Grant

Director Williams R. Sanders was granted 120,000 stock options in Tenaya Therapeutics, Inc. as part of the company's equity incentive plan.

Summary

• Director Williams R. Sanders received a grant of 120,000 stock options on May 28, 2026.
• The options have an exercise price of $0.7989 per share.
• The options are set to vest in full on May 28, 2027, or the day before the next annual stockholders meeting, whichever occurs first.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential for future shareholder dilution upon the exercise of these options.

Risks

• The value of the options is subject to market volatility and the future performance of Tenaya Therapeutics' common stock.

Future Outlook

The options vest in one year, contingent upon the director's continued service to the company.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board talent, aligning leadership with the long-term clinical and commercial milestones of the company.

Comparison to Industry Standards

• The grant of stock options to directors is consistent with standard corporate governance practices for small-cap biotechnology firms.
• The one-year vesting schedule is typical for annual director equity awards in the life sciences industry.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of options on May 28, 2027.

Key Dates

Keywords

Tenaya Therapeutics, TNYA, Form 4, Insider Trading, Stock Options, Equity Incentive Plan